All News

Women with early-stage breast cancer treated with breast-conserving therapy had significantly improved 10-year overall survival compared with women who underwent mastectomy without radiation therapy.

Finding personal interests to discuss with your patient won’t make it all better. but it only takes a moment to find a sliver of common ground­, something to make you two humans trying to fix a problem.

The US Food and Drug Administration granted approval to uridine triacetate (Vistogard) as a treatment for overdose of fluorouracil or capecitabine, which are administered for a number of malignancies.

The combination of radiation therapy plus cetuximab had higher rates of acute toxicity among patients with locally advanced squamous cell carcinoma of the head and neck compared with radiation therapy plus cisplatin.

Patients with metastatic or unresectable urothelial carcinoma who are treated with either carboplatin or cisplatin have high rates of vascular thromboembolic events.

As the lead caregiver at the bedside, the oncology nurse plays a pivotal role in preventing missteps in end-of-life care decisions and ensuring that providers carry out the wishes of patients and families.

Warfarin is an acceptable alternative to low-molecular-weight heparin for patients with cancer-associated thrombosis, according to a new study.

A new study validates therapeutic guidelines that recommend anticoagulant dose reductions for thrombocytopenia in cancer patients.

Both radiofrequency ablation and stereotactic body radiotherapy are effective in the treatment of inoperable, non-metastatic hepatocellular carcinoma.

Women who previously had a false-positive mammogram or biopsy are at higher risk for developing breast cancer for at least 10 years, according to a new study.

Following the USPSTF recommendation in 2012 against routine PSA screening, rates of screening and the incidence of early-stage prostate cancer have both declined.

In this interview we discuss the new American Cancer Society breast cancer screening guidelines and find out how they stack up with other recommendations for mammography screening.

In this November news roundup we highlight some of the top stories of the month, including several FDA approvals, new breast cancer guidelines, and more.

Today the FDA approved the PD-1 inhibitor nivolumab (Opdivo) as a single-agent frontline treatment for patients with BRAF wild-type advanced melanoma.

Innovative “adaptive” clinical trial designs are using molecular tools and biomarkers in ways that will streamline research efforts and bring new treatments more quickly to regulatory approval and clinical use.

Expression of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) is associated with poor glioblastoma outcomes.

The table of contents for the latest issue of the journal ONCOLOGY: Perspectives on the Treatment of Hematologic and Solid Malignancies.

HLA-A2-positive glioblastoma patients experienced more frequent immune responses to the dendritic-cell immunotherapy IDT-107, responses that may be associated with improved survival.

Adding the EGFR-targeting drug panitumumab to chemotherapy had no effect on survival in a group of patients with wild-type KRAS status advanced biliary tract cancer.

For men with prostate cancer undergoing radiation therapy, consumption of men’s health supplements are unlikely to prevent adverse events, metastasis, or cancer-related death.

New breast cancer screening guidelines from the American Cancer Society recommend pushing the start of screening back by 5 years and screening every other year rather than annually starting at age 55.

The American Society of Clinical Oncology (ASCO) updated their antiemetic guideline to include the use of a novel antiemetic combination for cancer patients.

An analysis of different breast cancer screening schedules suggests that biennial mammograms may be acceptable for postmenopausal women, but that premenopausal women likely need more frequent screening.

This management guide covers the treatment, diagnosis, and staging of prostate cancer.

This management guide covers the risk factors, symptoms, diagnosis, staging, and treatment of liver, gallbladder, and biliary tract cancers using radiation, surgery, and medical treatment.

This testicular cancer management guide covers the diagnosis, staging, and treatment of germ-cell tumors and seminoma.

This comprehensive guide for oncologists covers the diagnosis, staging, treatment, and management of esophageal cancer.

This management guide covers the screening, diagnosis, staging, and treatment of cervical cancers.

Carcinoma of the epithelial lining (endometrium) of the uterine corpus is the most common female pelvic malignancy. Factors influencing its prominence are the declining incidence of cervical cancer, longer life expectancy, and earlier diagnosis.

Malignancies have been detected in approximately 40% of all patients with acquired immunodeficiency syndrome (AIDS) sometime during the course of their illness.